GlassScriptPhysician profile
Andrea Betesh
NPI 1659637254
$3,787.01
in general payments reported to CMS, 2019-2025
26 companies · $1,847 in 2025
The $1,847 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $564 · 2024: $1,376 · 2025: $1,847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,767 · Education: $20.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,766.86 |
| Education | $20.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,396.14 | 2023-2025 | Rinvoq, Linzess, Viberzi |
| Janssen Biotech, INC. | $494.49 | 2023-2025 | Tremfya, Stelara |
| Genzyme Corporation | $238.70 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $189.75 | 2024-2025 | Xifaxan, Plenvu |
| Regeneron Healthcare Solutions, INC. | $161.57 | 2024-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $133.55 | 2025 | Voquezna |
| Evoke Pharma, INC. | $121.74 | 2023-2025 | Gimoti |
| Takeda Pharmaceuticals U.S.A., INC. | $113.90 | 2024-2025 | Entyvio, Eohilia |
| Aimmune Therapeutics, INC. | $106.21 | 2024-2025 | Zenpep, Vowst |
| Lilly USA, LLC | $97.12 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $88.69 | 2024-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $84.45 | 2023-2025 | Linzess |
| Celltrion USA INC. | $77.54 | 2023-2025 | Vegzelma, Zymfentra |
| Pfizer INC. | $77.33 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.83 | 2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $71.60 | 2025 | Rezdiffra |
| Celgene Corporation | $60.76 | 2023-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $39.95 | 2023-2024 | Dificid |
| Qol Medical, LLC | $27.70 | 2023 | Sucraid |
| Amgen INC. | $24.62 | 2023 | Avsola, Amjevita |
| Ferring Pharmaceuticals INC. | $24.03 | 2024 | Rebyota |
| Enterra Medical, INC. | $22.81 | 2024 | |
| Capsovision, INC. | $16.75 | 2024 | Capsocam Plus |
| Nestle Healthcare Nutrition INC. | $14.52 | 2023 | |
| Braintree Laboratories, INC. | $13.89 | 2024 | Suflave |
| Sandoz INC. | $13.37 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Betesh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.